Clinical Trial Update: Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating piribedil (Clarium) versus other non-ergot dopamine agonists in Parkinson's disease, focusing on vigilance and cognitive fun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Piribedil (piribedil)

Snippet

Sponsor: Desitin Arzneimittel GmbH | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED